Freeman Technology highlights relevance of the FT4 for DPI characterisation

Published: 2-Mar-2010
Manufacturing Regulatory Drug Delivery Analysis Pharmaceutical

Respiratory Drug Delivery (RDD) 2010, 25 - 29 April 2010, Florida, US

At Respiratory Drug Delivery (RDD) 2010, Freeman Technology will highlight the unique insight the FT4 Powder Rheometer offers DPI formulators. This message will be reinforced by a presentation of work from the University of Bath showing a direct correlation between the measured dynamic powder properties and fine particle dose (FPD), a measure of drug delivery efficiency.

Dynamic powder characterization with the FT4 directly quantifies powder flowability and the response of a formulation to air, a critical property for successful DPI development. To ensure efficient drug delivery a DPI formulation/device combination must be engineered to achieve aerosolisation of the dose to a respirable size during use.

Research at the University of Bath has shown a robust correlation between FPD and aerated energy, a measure of how the flowability of the powder changes with the amount of air flowing through it. This makes the FT4 an extremely useful tool for the development of DPI formulations, which are required to disperse easily, with more consistent and less patient dependent performance.

The FT4 combines dynamic testing methodologies with shear and bulk property measurement, to provide comprehensive, process relevant powder characterisation. Precision engineering in combination with well-defined, automated test procedures deliver exceptional reproducibility and sensitivity. With application know-how that has been gained from 10 years working with industry, Freeman Technology also provides extensive powder processing expertise alongside the FT4 Powder Rheometer.
See more

You may also like

Analysis

Global biopharma faces talent shortages and regulatory uncertainty, Cytiva’s 2025 Global Biopharma Index finds

Read more
Cytiva’s latest Global Biopharma Index, surveying 1250 executives across 22 countries, reveals that while supply chain resilience is improving, talent shortages and policy instability are threatening growth across the biopharma sector

Trending Articles

  1. Agility, scale and trust: the outsourcing model driving pharma forward Outsourcing in the pharmaceutical industry has long been viewed as a matter of convenience and a way to ease short-term capacity pressures or delay the decision to invest in costly new facilities. That framing no longer fits
  2. RION engages Lonza to scale manufacturing exosome based therapeutics Collaboration leverages RION’s proprietary biomanufacturing process to propel RION’s industry-leading clinical development pipeline towards late-phase trials and commercialisation for multiple regenerative medical conditions
  3. Merck and others pull back from UK: what it means for pharma manufacturing With pharma giant Merck pulling its own version of Brexit, what can the UK do to retain its drug manufacturing capabilities?
  4. Gerresheimer boosts Wertheim site with new production facility The new production hall will focus on RTF vials and innovative EZ-fill Smart packaging platform, with a total investment volume of around EUR €30 million
  5. Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio

Upcoming event

CPHI Frankfurt 2025

28–30 October 2025 | Exhibition | Frankfurt, Germany See all

You may also like

Analysis

Global biopharma faces talent shortages and regulatory uncertainty, Cytiva’s 2025 Global Biopharma Index finds

Cytiva’s latest Global Biopharma Index, surveying 1250 executives across 22 countries, reveals that while supply chain resilience is improving, talent shortages and policy instability are threatening growth across the biopharma sector
Manufacturing

Rentschler Biopharma expands services in Japan and South Korea ahead of BioProcess International Asia

Rentschler Biopharma will showcase its Rentschler Expression Platform and Development Services at BioProcess International Asia in Kyoto, underscoring its commitment to supporting biopharma partners across Japan and South Korea
You need to be a subscriber to read this article.
Click here to find out more.
Ingredients

Decoding your personal health ecosystem: the power of microbiome diagnostics and nutraceuticals

People often talk about a “gut instinct” or a “gut feeling.” Until recently, though, actually discussing digestive health might have seemed unusual, suggests Christina Casén, Senior Vice President, Clinical and Medical Affairs at Genetic Analysis AS
Manufacturing

Navigating SOE compliance: how to strengthen organic enforcement within your organisation

Part I of NSF’s webinar series explores strategies to meet rising regulatory demands, reduce fraud, and promote ethical practices
Manufacturing

Exploring Ireland’s thriving life sciences sector

NSF highlights its pivotal role in one of the world’s leading hubs for pharma and medical device manufacturing
Manufacturing

Quality control: the central pillar supporting peptide manufacturing

Amid the growing complexity and innovation in the field, this article explores how centralised quality control plays a pivotal role by ensuring both safety and consistency during custom peptide production
Manufacturing

Intertronics releases white paper on process validation for medical device bonding

The new guidance helps manufacturers cut costs, save time and ensure ISO and FDA compliance by designing out variability and improving process reliability from the start
Subscribe now